This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
PLEASANTON, Calif., Feb. 12, 2013 (GLOBE NEWSWIRE) -- ZELTIQ® Aesthetics, Inc. (Nasdaq:ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform, announced today that it plans to release its fourth quarter and full year 2012 financial results on Tuesday, March 12, 2013 after the market close.
ZELTIQ will hold a conference call on Tuesday, March 12, 2013, at 5:00 p.m. ET to discuss the results. The dial-in numbers are (877) 280-7291 for domestic callers and (707) 287-9361 for international callers. A live webcast of the conference call will be available online from the investor relations page of the Company's corporate website at
After the live webcast, the call will remain available on ZELTIQ's website,
www.coolsculpting.com, until ZELTIQ releases its first quarter 2013 financial results. In addition, a telephonic replay of the call will be available until March 19, 2013. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the replay pin number 99079360.
About ZELTIQ Aesthetics, Inc.
ZELTIQ® Aesthetics is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ's first commercial product, the CoolSculpting® System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues.
CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.
CONTACT: Investor Relations:
Patrick F. Williams
ZELTIQ, Senior Vice President and CFO
Nick Laudico / Amy Glynn
The Ruth Group
646-536-7030 / 7023